Generic placeholder image

Anti-Infective Agents

Author(s): Evgenii Plotnikov* and Vladimir Plotnikov

DOI: 10.2174/2211352520666220404143923

DownloadDownload PDF Flyer Cite As
Antibacterial and Phagocytic Properties of a Novel Silver-Interferon Complex

Article ID: e040422203080 Pages: 5

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Developing new antibacterial and antiviral drugs are considered a significant issue due to the emergence and spread of resistant strains of microorganisms. The COVID-19 pandemic has dramatically increased the need for new broad-spectrum anti-infective agents.

Objective: This experimental study aimed to investigate the antibacterial and phagocytic properties of silver-interferon preparation. The combination of properties of complex drugs makes them promising for treating drug-resistant infections and bacterial complications of viral diseases.

Methods: The antibacterial effect of the silver-interferon platform was investigated by agar diffusion and serial dilution methods. The drug's effect on the functional activity of phagocytes was studied on human neutrophils in a Staphylococcus aureus uptake test.

Results: Investigations have shown that the silver-interferon complex possesses a bactericidal mechanism of action against tested bacterial strains, including Streptococcus pneumonia, Salmonella enteritidis, Staphylococcus aureus, Escherichia coli. Streptococcus pneumonia was the most susceptible bacterial target for the tested complex, with a growth inhibition zone of 12±0.6 mm and a minimal bactericidal concentration of 0.08 mg/ml. A slight stimulating action of the drug in relation to the activity of phagocytes was revealed.

Conclusion: Silver-interferon has proved as a prospective anti-infective drug with a wide range of activities.

Keywords: Silver, interferon, antibacterial activity, immune-stimulation, nosocomial infections, phagocytosis.

Graphical Abstract

[1]
Feng, Q.L.; Wu, J.; Chen, G.Q.; Cui, F.Z.; Kim, T.N.; Kim, J.O. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J. Biomed. Mater. Res., 2000, 52(4), 662-668.
[http://dx.doi.org/10.1002/1097-4636(20001215)52:4<662:AID-JBM10>3.0.CO;2-3] [PMID: 11033548]
[2]
Silnikov, V.; Plotnikov, E.; Plotnikov, V. Pharmacokinetic studies of new silver-based complex. Int. J. Pharm. Pharm. Sci., 2015, 7, 41-43.
[3]
Plotnikov, E.; Plotnikov, V. Study of the antileukemic activity of a new silver-containing drug on the model of viral bovine leukemia. Int. J. Appl. Fundamental Res., 2017, 3, 89-92.
[4]
Boxx, G.M.; Cheng, G. The roles of Type I interferon in bacterial infection. Cell Host Microbe, 2016, 19(6), 760-769.
[http://dx.doi.org/10.1016/j.chom.2016.05.016] [PMID: 27281568]
[5]
Bogdan, C. The function of type I interferons in antimicrobial immunity. Curr. Opin. Immunol., 2000, 12(4), 419-424.
[http://dx.doi.org/10.1016/S0952-7915(00)00111-4] [PMID: 10899033]
[6]
González-Navajas, J.M.; Lee, J.; David, M.; Raz, E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol., 2012, 12(2), 125-135.
[http://dx.doi.org/10.1038/nri3133] [PMID: 22222875]
[7]
Kaplan, A.; Lee, M.W.; Wolf, A.J.; Limon, J.J.; Becker, C.A.; Ding, M.; Murali, R.; Lee, E.Y.; Liu, G.Y.; Wong, G.C.L.; Underhill, D.M. Direct antimicrobial activity of IFN-β. J. Immunol., 2017, 198(10), 4036-4045.
[http://dx.doi.org/10.4049/jimmunol.1601226] [PMID: 28411186]
[8]
Rizza, P.; Moretti, F.; Belardelli, F. Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity. Autoimmunity, 2010, 43(3), 204-209.
[http://dx.doi.org/10.3109/08916930903510880] [PMID: 20187707]
[9]
Sabar, M.F.; Kausar, S.; Zafar, A.U.; Shahid, M. PEG-interferon conjugates: Effects of length and structure of linker. Pak. J. Pharm. Sci., 2013, 26(2), 425-430.
[PMID: 23455218]
[10]
Xu, K.; Lee, F.; Gao, S.J.; Chung, J.E.; Yano, H.; Kurisawa, M. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy. J. Control. Release, 2013, 166(3), 203-210.
[http://dx.doi.org/10.1016/j.jconrel.2013.01.008] [PMID: 23328125]
[11]
Sim, W.; Barnard, R.T.; Blaskovich, M.A.T.; Ziora, Z.M. Antimicrobial silver in medicinal and consumer applications: A patent review of the past decade (2007−2017). Antibiotics (Basel), 2018, 7(4), 93.
[http://dx.doi.org/10.3390/antibiotics7040093] [PMID: 30373130]
[12]
Drake, P.L.; Hazelwood, K.J. Exposure-related health effects of silver and silver compounds: A review. Ann. Occup. Hyg., 2005, 49(7), 575-585.
[PMID: 15964881]
[13]
Jorgensen, J.H.; Ferraro, M.J. Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clin. Infect. Dis., 2009, 49(11), 1749-1755.
[http://dx.doi.org/10.1086/647952] [PMID: 19857164]
[14]
Novikov, D.K.; Novikova, V.A. Immune status assessment; Medicine: Moscow, 1996.
[15]
Asmana Ningrum, R. Human interferon alpha-2b: A therapeutic protein for cancer treatment. Scientifica (Cairo), 2014, 2014970315
[http://dx.doi.org/10.1155/2014/970315] [PMID: 24741445]
[16]
Abdolvahab, M.H.; Darvishi, B.; Zarei, M.; Majidzadeh-A, K.; Farahmand, L. Interferons: Role in cancer therapy. Immunotherapy, 2020, 12(11), 833-855.
[http://dx.doi.org/10.2217/imt-2019-0217] [PMID: 32635782]
[17]
Haji Abdolvahab, M.; Moradi-Kalbolandi, S.; Zarei, M.; Bose, D.; Majidzadeh-A, K.; Farahmand, L. Potential role of interferons in treating COVID-19 patients. Int. Immunopharmacol., 2021, 90107171
[http://dx.doi.org/10.1016/j.intimp.2020.107171] [PMID: 33221168]
[18]
Lee, A.J.; Ashkar, A.A. The dual nature of type i and type ii interferons. Front. Immunol., 2018, 9(9), 2061.
[http://dx.doi.org/10.3389/fimmu.2018.02061] [PMID: 30254639]
[19]
Slawson, R.M.; Lee, H.; Trevors, J.T. Bacterial interactions with silver. Biol. Met., 1990, 3(3-4), 151-154.
[http://dx.doi.org/10.1007/BF01140573] [PMID: 2073456]
[20]
Cavassin, E.D.; de Figueiredo, L.F.; Otoch, J.P.; Seckler, M.M.; de Oliveira, R.A.; Franco, F.F.; Marangoni, V.S.; Zucolotto, V.; Levin, A.S.; Costa, S.F. Comparison of methods to detect the in vitro activity of silver nanoparticles (AgNP) against multidrug resistant bacteria. J. Nanobiotechnology, 2015, 13(1), 64.
[http://dx.doi.org/10.1186/s12951-015-0120-6] [PMID: 26438142]
[21]
Smith, J.N.; Thomas, D.G.; Jolley, H.; Kodali, V.K.; Littke, M.H.; Munusamy, P.; Baer, D.R.; Gaffrey, M.J.; Thrall, B.D.; Teeguarden, J.G. All that is silver is not toxic: Silver ion and particle kinetics reveals the role of silver ion aging and dosimetry on the toxicity of silver nanoparticles. Part. Fibre Toxicol., 2018, 15(1), 47.
[http://dx.doi.org/10.1186/s12989-018-0283-z] [PMID: 30518385]
[22]
Zhang, T.; Wang, L.; Chen, Q.; Chen, C. Cytotoxic potential of silver nanoparticles. Yonsei Med. J., 2014, 55(2), 283-291.
[http://dx.doi.org/10.3349/ymj.2014.55.2.283] [PMID: 24532494]
[23]
Plotnikov, E.; Gapeyev, A.; Plotnikov, V. Investigation genotoxicity of new silver-based complex with antimicrobial activity. Int. J. Pharm. Pharm. Sci., 2015, 7, 454-455.
[24]
Kirkwood, J. Cancer immunotherapy: The interferon-alpha experience. Semin. Oncol., 2002, 3(7), 18-26.
[http://dx.doi.org/10.1053/sonc.2002.33078]
[25]
Quintana, M.E.; Barone, L.J.; Trotta, M.V.; Turco, C.; Mansilla, F.C.; Capozzo, A.V.; Cardoso, N.P. In-vivo activity of IFN-λ and IFN-α against bovine-viral-diarrhea virus in a mouse model. Front. Vet. Sci., 2020, 7(7), 45.
[http://dx.doi.org/10.3389/fvets.2020.00045] [PMID: 32118067]
[26]
Newby, B.N.; Brusko, T.M.; Zou, B.; Atkinson, M.A.; Clare-Salzler, M.; Mathews, C.E. Type 1 interferons potentiate human CD8+ T-Cell cytotoxicity through a STAT4- and granzyme B-Dependent pathway. Diabetes, 2017, 66(12), 3061-3071.
[http://dx.doi.org/10.2337/db17-0106] [PMID: 28877912]
[27]
Livonesi, M.C.; de Sousa, R.L.; Badra, S.J.; Figueiredo, L.T. In vitro and in vivo studies of the interferon-alpha action on distinct orthobunyavirus. Antiviral Res., 2007, 75(2), 121-128.
[http://dx.doi.org/10.1016/j.antiviral.2007.01.158] [PMID: 17368573]